Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 14/20 | 0.50 |
| ▸ | TYK2 | P29597 | 13/20 | 0.50 |
| ▸ | JAK3 | P52333 | 12/20 | 0.37 |
| ▸ | JAK2 | O60674 | 11/20 | 0.37 |
| ▸ | RET | P07949 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1160181 | 0.84 | JAK1 (0.53) | JAK1TYK2JAK3JAK2 | |
| SCHEMBL9899010 | 0.84 | JAK1 (0.53) | JAK1TYK2JAK3JAK2 | |
| SCHEMBL9897077 | 0.84 | JAK1 (0.53) | JAK1TYK2JAK3JAK2 | |
| SCHEMBL1160347 | 0.83 | JAK1 (0.47) | JAK1TYK2RET | |
| SCHEMBL9923088 | 0.80 | JAK2 (0.62) | JAK1TYK2JAK3JAK2 | |
| SCHEMBL9923428 | 0.77 | JAK1 (0.53) | JAK1TYK2JAK3JAK2 | |
| SCHEMBL1160281 | 0.75 | JAK1 (0.64) | JAK1TYK2JAK3JAK2 | |
| SCHEMBL12875537 | 0.75 | JAK1 (0.51) | JAK1TYK2JAK3JAK2 | |
| SCHEMBL1160504 | 0.75 | JAK1 (0.64) | JAK1TYK2JAK3JAK2 | |
| SCHEMBL1160503 | 0.74 | JAK1 (0.63) | JAK1TYK2JAK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | JAK1 1/4885TYK2 10/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.